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Summary
Background: Chronic established pain, especially that
following nerve injury, is difficult to treat and represents
a largely unmet therapeutic need. New insights are ur-
gently required, and we reasoned that endogenous pro-
cesses such as cooling-induced analgesia may point the
way to novel strategies for intervention. Molecular re-
ceptors for cooling have been identified in sensory
nerves, and we demonstrate here how activation of
one of these, TRPM8, produces profound, mechanisti-
cally novel analgesia in chronic pain states.
Results:We show that activation of TRPM8 in a subpop-
ulation of sensory afferents (by either cutaneous or intra-
thecal application of specific pharmacological agents or
by modest cooling) elicits analgesia in neuropathic and
other chronic pain models in rats, thereby inhibiting
the characteristic sensitization of dorsal-horn neurons
and behavioral-reflex facilitation. TRPM8 expression
was increased in a subset of sensory neurons after nerve
injury. The essential role of TRPM8 in suppression of
sensitized pain responses was corroborated by specific
knockdown of its expression after intrathecal applica-
tion of an antisense oligonucleotide. We further show
that the analgesic effect of TRPM8 activation is centrally
mediated and relies on Group II/III metabotropic gluta-
mate receptors (mGluRs), but not opioid receptors. We
propose a scheme in which Group II/III mGluRs would
respond to glutamate released from TRPM8-containing
afferents to exert an inhibitory gate control over noci-
ceptive inputs.
Conclusions: TRPM8 and its central downstream medi-
ators, as elements of endogenous-cooling-induced
analgesia, represent a novel analgesic axis that can be
exploited in chronic sensitized pain states.
*Correspondence: s.m.fleetwood-walker@ed.ac.uk (S.M.F-W.); rory.
mitchell@ed.ac.uk (R.M.)Introduction
Chronic neuropathic pain arising from peripheral nerve
damage is a severe clinical problem with limited treat-
ment options [1]. Changes in both damaged and undam-
aged primary afferent neurons as well as central (spinal
cord) sensitization lead to hyperalgesia (accentuated re-
sponses to painful stimuli), allodynia (pain in response to
normally innocuous stimuli), and spontaneous pain. We
hypothesized that elucidating the poorly understood
mechanisms underlying cold-induced analgesia might
lead the way to novel neuropathic analgesics.
Since Hippocrates and Galen [2, 3], sporadic reports
have described the use of cooling to produce analgesia
[4]. Clinical trials show beneficial effects of cooling on
chronic back pain, dental pain, postoperative pain,
and muscle injuries [5]. Preparations containing men-
thol, which produces a cool sensation, are used topi-
cally to relieve neuralgia in traditional Chinese and Euro-
pean medicine [6, 7]. Mint oil has been reported to
alleviate thermally elicited pain and postherpetic neural-
gia [8, 9], and oral menthol can cause short-term analge-
sia [10]. Furthermore, in mice, oral or intracerebroven-
tricular application of menthol decreased nociceptive
responses to the hot-plate test and acetic-acid writhing
test [11]. Despite this history, no definitive mechanism
has been established for cool-induced analgesia.
The recent isolation of the transient receptor potential
(TRP) cation channels present in primary sensory neurons
has revolutionized our understanding of cutaneous tem-
perature detection. The best-characterized example is
the capsaicin- and heat-sensitive TRPV1 receptor [12],
and although much less is known about cool-sensitive
TRPs, they are the target of intensive research [13].
TRPM8 is activated at innocuous cool temperatures
(with 50% activation around 18C–19C [14]) and by men-
tholand icilin [15,16], which actasselective (but not totally
specific) activators of the channel [14, 17]. The TRPM8
channel is expressed by a subpopulation of sensory neu-
rons in dorsal root ganglia (DRG) and trigeminal ganglia
[15, 16], where responses to cooling correlate well with
mRNA expression and menthol sensitivity [18–20].
The TRPA1 channel is also expressed in DRG and tri-
geminal ganglia [14, 21] and is reportedly activated by
cooling temperatures beginning 5C–6C lower than
that for TRPM8 [14, 22] and by noxious chemicals
such as cinnamaldehyde and mustard oil [14, 22, 23].
However, the role of TRPA1 in physiological cold sen-
sation is currently unclear [13], with some reports of
TRPA1 not being activated by cold [21, 23] and of normal
cold sensitivity in TRPA1 knockout mice [24]. In con-
trast, another study of TRPA1 knockout mice reported
attenuated responses to noxious cold [25], and anti-
sense knockdown studies show a decrease in develop-
ment of nerve-injury- or inflammation-induced hyper-
algesia to intense cold stimuli [26, 27]. On balance,
TRPA1 seems a less likely candidate than TRPM8 for
the mediator of cooling-induced analgesia.
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because cutaneous cooling can prevent pain produced
by afferent stimulation [4]. Glutamate-receptor-depen-
dent plasticity in spinal cord neurons commonly under-
lies chronic pain states with both ionotropic and metab-
otropic receptors participating at pre- and postsynaptic
sites. Although most glutamate receptors are excitatory,
the Group II/III metabotropic receptor (mGluR) subtypes
exert inhibitory influences, suggesting the hypothesis
that they could potentially underpin cooling-induced an-
algesia. Indeed, Group II and III mGluRs are present in
the spinal cord largely on afferent terminals, but with
some glial and postsynaptic expression [28, 29], and
their activation inhibits both nerve-injury- and inflamma-
tion-induced sensitization of neuronal and behavioral
responses [30–32].
Here we demonstrate marked analgesic effects of pe-
ripherally or centrally applied TRPM8 activators (such as
icilin or menthol), or mild cooling of the skin, in a model
of neuropathic pain. TRPM8 levels in DRG and superfi-
cial dorsal horn were increased after nerve injury. Anal-
gesia was restricted to injury-sensitized responses and
abolished after antisense knockdown of TRPM8. Pe-
ripheral application of icilin or menthol also activated
slowly conducting afferents (in a TRPM8-antisense-sen-
sitive manner) and suppressed the increased respon-
siveness of single dorsal-horn neurons ipsilateral to
nerve injury. In contrast, activation of TRPA1 produced
hyperalgesia (in both naive animals and nerve-injured
animals). TRPM8-mediated analgesia was selectively
reversed by intrathecal administration of Group II/III
mGluR antagonists and mimicked by agonists, and ion-
ophoresis of a Group III mGluR antagonist, as an exam-
ple, reversed the inhibitory effect of icilin on sensitized
single neurons. Sensitization-specific analgesia from
TRPM8 activation was also observed in inflammatory
afferent demyelination and TRPA1 activator-induced
pain models.
Results
Reversal of Nerve-Injury-Induced Reflex
Sensitization by Peripheral Activation
of TRPM8 Channels
In order to model potential clinical usage, we adminis-
tered icilin topically to the paws by placing rats with
chronic constriction injury (CCI) to sciatic nerve in a
bath with 1-cm-deep drug solution, kept at 30C to avoid
any effects on local skin temperature. After 5 min, icilin
(80 mM), but not vehicle (0.2% dimethylformamide in wa-
ter), caused striking reversal of CCI-induced behavioral-
reflex sensitization to thermal and mechanical stimuli
(Figure 1A). Concentration-dependent effects were ob-
served from 2.5 mM up to a maximum of 500 mM, with
no effect on contralateral or naive responses (Figure 1B).
At much higher concentrations of icilin, we observed the
beginning of a trend toward increasing reflex sensitivity,
ipsilateral and contralateral to CCI and in naive animals
(Table 1), that was statistically significant in mechanical
and (after a delay) in thermal tests, only at the highest
concentration tested, 5 mM. This effect was distinct
from the prominent analgesia at low concentrations of
icilin because it was not specific to a sensitized stateand may be due to weak interaction with other targets
or nonspecific actions. Specific reversal of sensitized re-
sponses was also caused by another selective TRPM8
activator, (2)-menthol (4 mM). The stereoisomers iso-
menthol and (+)-menthol, which are several-fold-less-
potent agonists of TRPM8 [33, 34], also produced rever-
sal of sensitized responses at concentrations of 8 mM
and 16 mM (Figure 1C).
Icilin is expected to activate TRPM8-containing affer-
ents, so we recorded firing activity in saphenous-nerve
afferents after topical application of icilin (Figure 1D).
The nerve was dissected to produce small-number
preparations of fine afferents, with conduction velocities
of up to 2.6 m/s (representing C- and Ad-fiber afferents
[35]). Icilin (200 mM) applied to the receptive field on
the hind limb caused a significant increase in firing fre-
quency in 21.6% (40 out of 185) of recorded fine affer-
ents with a mean 7-fold increase in firing frequency
from baseline of 4.5 6 2.5 Hz to 31.6 6 3.4 Hz and
a mean time to peak effect of 3.3 6 0.5 min. Icilin did
not produce rapid desensitization, agreeing with some
reports [36] but not others [37]. Recovery was consis-
tently observed. Similar results were obtained from
both hairy and glabrous skin. Large myelinated mecha-
noreceptors (conduction velocities 6.8–15 m/s, n = 43)
were unaffected.
Consistent with a TRPM8-mediated mechanism, paw
immersion at 16C–20C for 5 min also produced statis-
tically significant mechanical analgesia (Figure 1E). Re-
cordings from a subcutaneous thermistor probe showed
that deep skin temperatures were 0.5C above bath
temperatures after 5 min in similar conditions. This tem-
perature is in the range expected to activate TRPM8 and
stimulate innocuous cool-sensitive fibers. Immersion
temperatures below 14C (in the range where other
cold sensors, in addition to TRPM8, are also likely to
be activated) elicited active nociceptive withdrawal re-
flexes limited to the period of hind paw immersion, in
agreement with the known temperature activation range
for nociceptive cold fibers [38].
Localization of TRPM8 in Afferents and Superficial
Dorsal Horn: Increased Expression after Nerve Injury
The presence and localization of TRPM8 in DRG and the
spinal cord were investigated by immunoblotting and
immunohistochemistry. After rapid homogenization of
DRG in Laemmli lysis buffer and SDS-PAGE, immuno-
blots probed with a rabbit polyclonal antibody raised to
TRPM8 residues 278–292 and 1090–1104 (human) [39]
showed a single, strong band at approximately 128
kDa (the predicted molecular weight of TRPM8), with
faint bands observed at approximately 170, 60, and
50 kDa (Figure 2A). Both antigen-preabsorbtion and
antisense-knockdown controls were consistent with
specificity of this antibody in recognition of TRPM8 at ap-
proximately 128 kDa under the conditions used. Preincu-
bation of the antibody with membranes from COS7 cells
transfected with TRPM8 expression plasmid abolished
the band at 128 kDa, whereas sham preabsorbtion with
membranes from cells with empty vector did not (Fig-
ure 2A). Correspondingly, intrathecal delivery of a
TRPM8 antisense oligonucleotide to naive (non-CCI)
rats over 5 days also resulted in almost complete knock-
down of the 128 kDa band (Figure 2A), whereas a
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(A, B, C, and E) Behavioral data from CCI animals, shown as mean 6 SEM; each graph represents n of six animals.
(A) Paw withdrawal latency (PWL; s) to noxious heat and paw withdrawal threshold (PWT; mN/mm2) to mechanical stimuli before and after 5 min
paw immersion in a shallow 30C water bath containing 80 mM icilin or vehicle.B: ipsilateral paw plus icilin; : ipsilateral + vehicle;-: contra-
lateral plus icilin, : contralateral plus vehicle. * indicates significant ipsilateral-contralateral differences; y indicates significant difference from
predrug baseline (p < 0.05).
(B) Concentration-response curve for mean 6 SEM percentage reversal of ipsilateral sensitization for thermal (B) or mechanical (A) tests
calculated over 10–15 min after paw immersion in 2.5–500 mM icilin.
(C) Reversal of ipsilateral sensitization by paw immersion in (2)-menthol at 4 mM, and by higher concentrations of the less-potent stereoisomers
(+)-menthol and isomenthol (8 and 16 mM). Values were calculated over 10–25 min after paw immersion from experiments as shown in (A).
y indicates significant differences from predrug baseline (p < 0.05).
(D) Typical electrophysiological recording from the subpopulation of icilin-responsive C fiber afferent fibers before, 2 min after topical application
of icilin to the receptive field (peak effect), and 12 min later.
(E) Mechanical analgesia measured over 5 min after 5 min immersion of paws at the indicated temperature range. x denotes spontaneous with-
drawal responses during the immersion period, * denotes significant difference from contralateral paw, and y denotes significant difference from
preimmersion baseline (p < 0.05).missense control oligonucleotide was ineffective (see
below). Intrathecally delivered fluorescent-labeled oligo-
nucleotides have been shown to effectively penetrate
the DRG, as soon as 4 hr after initial delivery [40]. The
faint bands, at 50 and 60 kDa at least, remained present
in each case and so are likely to represent nonspecific in-
teractions of the antibody under these conditions. As fur-
ther controls, we showed that TRPV1 immunoreactivity
was unaffected by treatment with the TRPM8 antisense
reagent and that the housekeeping enzyme GAPDH (36
kDa) was evenly present in each lane (Figure 2A). After
nerve injury, there was a marked increase in expression
of the 128 kDa TRPM8-immunoreactive band specifically
in ipsilateral, but not contralateral, DRG (Figure 2A),whereas immunoreactivity for GAPDH was unaltered.
Densitometric ratios for TRPM8 expression as percent-
age of GAPDH were 80.7 6 4.1 ipsilateral to CCI, which
was significantly greater than that seen contralateral to
CCI (49.3 6 3.2) and in naive DRG (50.7 6 2.7) (mean 6
standard error of the mean [SEM], n = 5–6). L4–5 spinal
cord extracts showed that TRPM8 immunoreactivity
was present centrally, and after preparation of a crude
particulate fraction (centrifugation at 11,000 3 g for 45
min), these also showed consistent increases in expres-
sion ipsilateral to injury. Densitometric values ipsilateral
to CCI were 198% 6 6.7% of those from naive tissue
(p < 0.05; mean 6 SEM, n = 5), whereas contralateral
values were 125% 6 7.1% (p > 0.05).
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1594Table 1. Analgesic Effects of Topically Administered Icilin against Neuropathic Sensitization Revert at Very High Concentrations to a General
Nociceptive Effect
Reflex Response Sensitivity at Different Times after Icilin Application to Paw
Thermal PWL (s)
Drug Concentration (mM) Naive CCI Ipsi CCI Con
Predrug Baseline 15.5 6 0.2 9.7 6 0.2 16.4 6 0.2
15 min 50 min 15 min 50 min 15 min 50 min
0 (vehicle) 15.1 6 1.2 14.9 6 0.8 9.8 6 1.1 9.7 6 0.9 15.2 6 0.6 15.1 6 0.7
1000 15.1 6 1.2 14.8 6 0.9 16.4 6 0.8a 8.6 6 0.2 16.1 6 0.5 15.2 6 0.4
2500 14.9 6 0.3 13.2 6 0.8 16.4 6 0.9a 8.4 6 0.6 16.8 6 0.9 15.3 6 0.7
5000 15.3 6 0.5 13.1 6 0.7b 16.7 6 1.0a 7.2 6 0.6b 16.1 6 0.9 13.4 6 0.7b
Mechanical PWT (mN/mm2)
Drug Concentration (mM) Naive CCI Ipsi CCI Con
Predrug Baseline 4830.6 6 0.0 805.7 6 26.3 4793.6 6 37.5
15 min 50 min 15 min 50 min 15 min 50 min
0 (vehicle) 4830.6 6 0.0 4830.6 6 0.0 805.7 6 26.3 805.7 6 26.3 4830.6 6 0.0 4830.6 6 0.0
1000 4830.6 6 0.0 4830.6 6 0.0 702.8 6 185.3 702.8 6 185.3 4530.1 6 300.5 4530.1 6 300.5
2500 4830.6 6 0.0 4830.6 6 0.0 651.9 6 193.0 651.9 6 193.0 4454.9 6 245.9 4454.9 6 245.9
5000 3828.6 6 316.8b 4830.6 6 0.0 412.2 6 24.3b 736.0 6 26.3 2040.2 6 115.2b 4830.6 6 0.0
Significant effects of drug on reflex responses are indicated:
a Significant increase from baseline, indicating analgesic effect of icilin.
b Significant decrease from baseline values, indicating hyperalgesic effects.Immunohistochemistry was carried out with a rabbit
polyclonal antibody raised to TRPM8 residues 656–680
(rat) [41], the specificity of which was addressed by
antigen-preabsorbtion and antisense-knockdown con-
trols. The labeling observed in a discrete subpopulation
of DRG cells was abolished after preincubation with the
peptide antigen (no positive cells seen, counted over
twelve 500 mm2 sections, compared with a mean of
5.36 0.4 TRPM8-positive cells per 500 mm2 DRG section
with sham treatment of antibody, and 5.16 0.5 TRPM8-
positive cells per 500 mm2 DRG section with untreated
antibody, counted over 12 sections each). In immuno-
blots, the antibody also labeled in naive DRG tissue
a single band, at approximately 128 kDa, that was abol-
ished either by preabsorbtion with the peptide antigen
or by prior 5 day intrathecal infusion of TRPM8 antisense
(Figure 2B). Immunohistochemical staining in the spinal
cord showed that TRPM8 was largely expressed in the
superficial dorsal horn, like the C fiber marker peripherin
(Figure 2C), and that after dorsal rhizotomy (L2–6), the
vast majority of TRPM8 (and peripherin) immunoreactiv-
ity was lost ipsilaterally (reductions of approximately
80%–90%), suggesting that spinal TRPM8 originates
largely from afferents. In confirmation of the immunoblot
findings, levels of TRPM8-like immunoreactivity were
increased in the dorsal horn ipsilateral to injury (by ap-
proximately 70%–80%), but retained a similar distribu-
tion to that in naive animals (Figure 2D).
To establish whether the increases in afferent TRPM8
expression occurred in specific subpopulations of DRG
cells, we investigated TRPM8 colocalization with mark-
ers of myelinated afferents (neurofilament-200; NF-200
[42]) and unmyelinated afferents (peripherin [43]). In
naive rats, TRPM8 immunoreactivity was largely con-
fined to a subpopulation of unmyelinated DRG cells
(8.3%6 0.2% of peripherin-positive cells; 34 of 408 cells)
and only minimally expressed in myelinated, NF-200-
positive cells (1.3% 6 0.5%; 6 of 445 cells). However,after CCI, TRPM8 expression was significantly increased
ipsilaterally in both NF-200- and peripherin-positive
cells, to 7.9% 6 1.2% (31 of 390 cells) and 15.5% 6
0.8% (64 of 412 cells), respectively. Corresponding con-
tralateral values were unaltered from naive values, at
2.0% 6 0.4% (14 of 346 cells) and 9.2% 6 0.4% (42 of
452 cells) (Figures 2E and 2F). Data were taken from 3
CCI and 3 naive animals and counted across 15–21 sec-
tions. The additional TRPM8-expressing NF-200-posi-
tive cells were small (average diameter, 19.7 6 0.8 mm),
presumed Ad myelinated neurons [35]. There were no
significant differences in the diameters of NF-200- or
peripherin-positive cells or in the numbers of NF-200-
or peripherin-positive DRG neurons per section.
Molecular Identification of TRPM8 as the Mediator
of Icilin-Induced Analgesia
To define the specific involvement of TRPM8 in icilin
analgesia, we further utilized the antisense-oligonucleo-
tide knockdown strategy. TRPM8 antisense or mis-
matched control oligonucleotides were delivered intra-
thecally over 13 days to parallel the sensitization
developing after CCI. The development of CCI-induced
behavioral-reflex sensitization was unaffected, includ-
ing thermal hyperalgesia and mechanical allodynia (Fig-
ures 3A and 3B) and cold allodynia (control CCI animals
showed elevation of the paw ipsilateral to nerve injury
out of 4C water for 8.1 6 0.5 s at peak, 9–11 days after
surgery, whereas corresponding values in antisense-
treated CCI animals were 7.6 6 0.6 s). In contrast, the
reversal of neuropathic reflex sensitization produced
normally by 80 mM icilin applied to the paws (Figure 1A)
was abolished by treatment with antisense (Figure 3A),
but not missense (Figure 3B), reagents. The mean 6
SEM reversals of ipsilateral sensitization over 10–25
min after icilin treatment in antisense- and missense-
treated animals were 7.7% 6 7.4% and 82.8% 6 6.9%,
respectively, for paw withdrawal latency (PWL), and
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threshold (PWT), with missense-treated, but not anti-
sense-treated, animals retaining significant effects of
icilin (p < 0.05). When antisense osmotic pumps were
depleted, but animals were still neuropathic (18 days af-
ter surgery for insertion of 14 day minipumps and CCI),
responses to icilin were restored to 83.7% 6 10.1% re-
versal of sensitization for PWL and 54%.0 6 7.2% for
PWT. Effectiveness of knockdown was assessed by
SDS-PAGE/immunoblotting. Expression of the 128 kDa
TRPM8-immunoreactive band in both ipsilateral and
contralateral DRG was greatly reduced by the antisense
reagent, and the increase in TRPM8 expression normally
seen ipsilateral to nerve injury was prevented
(Figure 3C). The missense reagent had no effect
(Figure 3C), showing TRPM8 expression similar to that
in untreated CCI animals (Figure 2A). In missense-
treated animals, TRPM8:GAPDH ratios were 77.9% 6
2.0% ipsilateral to CCI and 52.9% 6 2.1% contralateral,
similar to corresponding control values (Figure 2A and
above), whereas in antisense-treated animals, values
were much lower (19.8% 6 2.2% and 14.9% 6 2.1%,
respectively, mean 6 SEM, n = 5).
To confirm that antisense knockdown of TRPM8 re-
sulted in associated functional changes in afferents,
we made saphenous-nerve recordings from naive ani-
mals receiving intrathecal delivery of TRPM8 antisense
or missense oligonucleotides, 4–5 days after insertion
of the pump. The increase in firing frequency evoked
by topical icilin (200 mM) was strongly reduced in animals
receiving antisense. Only 3 out of 34 recorded slowly
conducting fibers (8.8%) showed a partial activation in
response to the drug, increasing firing by approximately
2-fold from a baseline of 5.86 1.4 to 12.76 0.6 Hz, com-
pared with the 7-fold increase observed in over 20% of
fine afferents in naive animals. In contrast, missense an-
imals showed a 7-fold increase in firing frequency in
25% of 40 recorded fibers from a baseline of 3.3 6 0.7
to 23.1 6 3.2 Hz, similar to results from naive animals.
Similarly, in missense-treated animals, topical (2)-men-
thol (4 mM) produced an approximately 8-fold increase
in mean firing frequency (from 4.5 6 2.9 to 38.9 6 7.6
Hz), activating 20% of fibers (35 identified afferents re-
corded). This compared with no obviously activated af-
ferents in antisense-treated animals (mean firing fre-
quency 4.0 6 1.8 Hz at background, 4.8 6 1.9 Hz after
drug application, 28 identified afferents recorded). How-
ever, TRPM8 antisense treatment did not alter the effect
of topically applied resiniferatoxin (1 mM), a potent
TRPV1 agonist acting as a control. In antisense-treated
animals, resiniferatoxin evoked a 6-fold increase in firing
frequency in activated afferents (from 4.56 0.7 baseline
to 25.96 1.8 Hz at peak response, 16 afferents activated
out of 28 recorded), which was similar to responses
in missense-treated animals (showing a mean 5-fold
change in firing frequency from 4.6 6 2.8 to 24.8 6
3.1 Hz).
Central Intrathecal Administration of TRPM8
Activators Also Inhibits Neuropathic Sensitization
Because TRPM8 is present on central terminals of pri-
mary sensory neurons as well as their peripheral termi-
nals (Figures 2B and 2C, [44, 45]), we investigated
whether intrathecal application of TRPM8 activatorsnear the central terminals would also produce analgesia.
Intrathecal injection of icilin (10 nmol) produced robust
reversal of CCI-induced behavioral-reflex sensitization
in thermal and mechanical tests (Figure 4A, p < 0.05
for up to 55 min). Intrathecal injection of (2)-menthol
(200 nmol) in CCI rats also caused a significant reversal
of the sensitized responses, lasting 35–40 min
(Figure 4B). Because of the higher potency and efficacy
of icilin at TRPM8 [15], further experiments mainly uti-
lized icilin as the representative TRPM8 activator. Icilin
produced dose-dependent analgesic effects restricted
to the nerve injury side in both thermal and mechanical
tests that were statistically significant by 0.125 nmol
and increased to almost complete reversal of sensitiza-
tion by 10 nmol. Nonlinear curve-fitting indicated that
maximal effects of icilin were similar for PWL and PWT
(91.6%6 9.9% and 82.6%6 6.8% reversal of sensitiza-
tion, respectively), as were EC50 values (dose for 50% of
maximal effect; 0.17 6 0.02 nmol and 0.31 6 0.02 nmol,
respectively).
In complete contrast to the effects of TRPM8 activa-
tors, the TRPA1 activator, cinnamaldehyde [22] (75
nmol injected intrathecally), significantly increased re-
flex responsiveness in thermal and mechanical tests
and was effective contralateral as well as ipsilateral to
nerve injury (Figure 4C). The sensitizing effects of cinna-
maldehyde were prevented by coinjection of Ruthenium
Red (0.25 nmol), which can block TRPA1 channels [21,
46], whereas the analgesic effect of intrathecally injected
icilin was unaffected (Figure 4D). Sensitizing effects of
cinnamaldehyde were also seen in naive animals, with
a 36.9% 6 7.9% reduction in PWL and a 41.9% 6 6.7%
reduction in PWT. Similar effects were produced by
two further TRPA1 activators [46, 47], allicin (25 nmol),
where corresponding reductions were 33.2% 6 5.9%
and 20.7% 6 8.2%, respectively, and diallyl disulphide
(50 nmol), with equivalent values of 25.9% 6 7.0% and
28.5% 6 6.2% (mean 6 SEM, n = 3–6). In contrast, the
TRPM8 activators icilin (10 nmol) and (2)-menthol
(200 nmol) were without effect in naive animals (data
not shown). Topical application of cinnamaldehyde (1.5
mM) also produced bilateral sensitization of behavioral
reflexes in naive animals (mean decrease of 32.0% 6
8.6% in PWL and 20.2% 6 8.2% in PWT, p < 0.05, n =
6). This corresponds to the licking and shaking behavior
as well as the decrease in PWL reported after intraplantar
injection of cinnamaldehyde [22].
In further experiments, we investigated whether the
sensitized pain behaviors caused by TRPA1 activators
or other pain models were susceptible to icilin-induced
analgesia. Sensitization caused by intrathecal or topical
cinnamaldehyde was markedly attenuated by intrathe-
cal icilin (Table 2). The effect of topical cinnamaldehyde
was additionally reversed by topical icilin (200 mM, data
not shown). Sensitization caused by focal demyelination
of the sciatic nerve [43] or intraplantar injection of Com-
plete Freund’s Adjuvant (CFA) was also significantly
inhibited by intrathecal icilin (Table 2).
Central Mechanism of Icilin Reversal of Neuropathic
Sensitization Involves mGlu Group II/III Receptors
Because topical icilin increases activity in fine afferents
(Figure 1D) and both intrathecal and topical icilin reverse
nerve-injury-induced sensitization, centrally mediated
Current Biology
1596Figure 2. TRPM8 Immunoreactivity Is Present in DRG and Spinal Cord, Arises from Afferents, and Is Increased Ipsilateral to CCI
(A) Immunoblots of DRG show whole gels with TRPM8 protein running at 128 kDa and additional faint bands at approximately 170, 60, and
50 kDa, in normal rat DRG with specific knockdown of the 128 kDa band in DRG from antisense-treated animals. In additional controls, when
the TRPM8 antibody was preincubated with membranes from TRPM8-expressing cells, the 128 kDa immunoreactive band was removed,
whereas sham treatment had no effect. Blots additionally show GAPDH loading controls. TRPV1 expression (single band atw90 kDa) was un-
altered in DRG from TRPM8 antisense-treated animals. Immunoblots for TRPM8 protein showed a clear increase in expression of the specific
128 kDa band in DRG ipsilateral (‘‘ipsi’’) to nerve injury compared to contralateral (‘‘con’’) and naive DRG, with no change in GAPDH. Spinal cord
(SC) whole lysates showed no discernable changes in TRPM8 levels; however, increased levels ipsilateral to nerve injury were seen in crude
particulate fractions.
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(A and B) Paw withdrawal latency (PWL, s) to noxious heat and paw withdrawal threshold (PWT; mN/mm2) to mechanical stimuli are shown
ipsilateral (B) or contralateral (-) to CCI animals with antisense (n = 12) or missense (n = 10) treatments. Data show mean 6 SEM.
(A) The analgesia normally elicited by topical icilin was not observed after antisense knockdown of TRPM8 receptor indicated by the persistence
of significant ipsilateral-contralateral differences in PWL and PWT (* p < 0.05).
(B) In contrast, after missense treatment, icilin produced a significant reversal of CCI-induced ipsilateral sensitization in PWL and PWT responses
in comparison to baseline values (y p < 0.05), as in untreated CCI animals (Figure 1A).
(C) Immunoblots of DRG tissue probed for TRPM8 and GAPDH protein levels after TRPM8 antisense or missense treatment. TRPM8 expression
(and the increase in expression normally seen ipsilateral to CCI, Figure 2A) was selectively reduced by antisense, but not missense, infusion,
whereas GAPDH levels were unchanged.events are likely to be important in icilin action. Icilin-re-
sponsive afferents are expected to release glutamate,
so we hypothesized that inhibitory glutamate receptors
in the dorsal horn might underlie icilin-induced analge-
sia. Group II/III mGluRs could subserve such a role be-
cause they are antinociceptive in models of inflamma-
tory, neuropathic, and acute pain [30–32] and inhibit
transmission between primary afferent and spinal cord
neurons in sensitized states [48, 49]. Group II mGluRsare localized on primary afferent terminals in lamina II,
particularly in small nociceptive afferents [28, 50], al-
though some are found postsynaptically and on glia
[29]. Group III mGluRs are also found presynaptically
in the dorsal horn and are 45% coexpressed with either
IB4 or Substance P (markers of small nociceptive neu-
rons [51]). To assess whether activation of Group II/III
mGluRs might mimic icilin reversal of neuropathic sensi-
tization, we intrathecally injected the selective Group II(B) shows western blots of DRG from naive or TRPM8 antisense-treated rats probed with the TRPM8 antibody used for immunohistochemistry
in (C)–(F) below. Pretreatment of the antibody with the antigenic peptide or TRPM8 antisense treatment removed the single specific band
atz128 kDa.
(C) L5 spinal cord sections taken 8 days after dorsal rhizotomy were immunostained for peripherin (green) and TRPM8 (red) and showed marked
reduction of both proteins ipsilateral to rhizotomy.
(D) Immunostaining for TRPM8 (red) and the neuronal marker NeuN (green) in the spinal cord dorsal horn from CCI animals showed that TRPM8
was increased ipsilateral to CCI with no change in distribution, whereas NeuN levels were unchanged. Scale bar for (C) and (D) represents 500 mm.
(E and F) Immunohistochemical colocalization in DRG sections ipsilateral or contralateral to nerve injury and in naive animals of TRPM8 (red) with
(E) NF-200 (green) or (F) peripherin (green). In naive animals, TRPM8 is mainly located in peripherin-positive C fibers, with little or no apparent
expression in myelinated (NF-200) cells. Ipsilateral to nerve injury, TRPM8 expression was increased markedly in small NF-200-positive cells,
whereas a lesser increase in TRPM8:peripherin coexpression was also observed. Scale bar represents 50 mm. The bar charts in (E) and (F)
show the percentage coexpression (mean 6 SEM) for TRPM8:NF-200 and TRPM8:peripherin, respectively; actual cell counts are shown above
columns. Statistically significant increases in the percentage coexpression values were seen in both cases ipsilateral to CCI, p < 0.05 (*).
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1598Figure 4. Central TRPM8 Activation Is Analgesic after CCI, whereas TRPA1 Activation Is Hyperalgesic
Paw withdrawal latency (PWL, s) to noxious heat and paw withdrawal threshold (PWT, mN/mm2) to mechanical stimuli are shown ipsilateral (B)
or contralateral (-) to CCI. * denotes significant ipsilateral-contralateral differences (* p < 0.05). Data show mean 6 SEM, and each test repre-
sents n of six animals unless otherwise indicated. Rats were intrathecally injected (at arrow). The TRPM8 activators (A) icilin (10 nmol) and (B) (2)-
menthol (200 nmol) both significantly reversed ipsilateral thermal and mechanical sensitization in comparison to preinjection values (y, p < 0.05).
(C) In contrast, intrathecal application of the TRPA1 activator cinnamaldehyde (75 nmol) produced bilateral hyperalgesia and allodynia in CCI
animals. x (p < 0.05) shows statistically significant increases in thermal and mechanical reflex responsiveness of both ipsilateral and contralateral
paws.
(D) shows that Ruthenium Red (0.25 nmol) inhibits cinnamaldehyde (75 nmol)-induced hypersensitivity, but not icilin (10 nmol)-mediated anal-
gesia, ipsilateral to CCI. Values are mean 6 SEM, n = 4. Statistically significant changes in PWL/PWT values as a result of cinnamaldehyde or
icilin compared to predrug baseline are shown as x and y, respectively (p < 0.05), and for Ruthenium Red-reversal of the effect of cinnamaldehyde
(yy, p < 0.05).
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1599Table 2. Reversal of Sensitization by Intrathecal Icilin Administration in Different Pain Models
Pain Model
PWL (s)
Difference
from Control
(no drug)
PWL (s)
Difference
from Control
(+ icilin)
Mean %
Reversal of
Thermal Sensitization
(after 15–30 min)
PWT (mN/mm2)
Difference from
Control
(no drug)
PWT (mN/mm2)
Difference from
Control
(+ icilin)
Mean % Reversal
of Mechanical
Sensitization
(after 15–30 min)
CCI 5.9 6 0.9a 0.9 6 1.2b 84.7 6 6.0 3347.4 6 126.3 a 775.4 6 467.7b 76.8 6 5.3
CFA 4.7 6 0.9a 1.6 6 1.6b 66.0 6 7.5 2975.6 6 245.5a 1707.6 6 149.9b 42.6 6 2.8
Lysolecithin 7.8 6 1.0a 2.4 6 1.2b 69.2 6 5.1 3003.8 6 182.4a 1102.5 6 422.5b 63.3 6 6.4
Cinnamaldehyde
(intrathecal)
5.9 6 0.9a 0.5 6 1.8b 91.5 6 4.1 2022.6 6 375.4a 150.3 6 125.2b 92.6 6 2.8
Cinnamaldehyde
(topical)
5.0 6 1.5a 0.4 6 1.6b 92.0 6 6.1 1002.0 6 316.8a 0.0 6 0.0b 100.0 6 0.0
a Significant ipsilateral-contralateral differences in surgical pain models or, in the case of cinnamaldehyde-induced responses, differences from
prior baseline, are indicated (p < 0.05).
b Significant icilin (10 nmol, intrathecal)-induced reversal of sensitization is indicated (p < 0.05).or III mGluR agonists 2R, 4R-APDC or ACPT-III and AP-
4, respectively. 2R, 4R-APDC (15 nmol) caused 72.1%6
6.4% reversal of thermal and 56.0%6 10.9% reversal of
mechanical reflex sensitization ipsilateral to CCI (15–30
min postinjection) with no effect on contralateral re-
sponses. ACPT-III and AP-4 (150 nmol each) also re-
versed thermal sensitization (by 83.6% 6 6.3% and
60.8%6 6.7%, respectively), as well as mechanical sen-
sitization (65.7% 6 11.4% and 60.7% 6 8.0%), again
with no effects contralaterally (p < 0.05 in each case).
Furthermore, selective Group II and Group III mGluR an-
tagonists LY 341495 (5 nmol, Figure 5A) and UBP 1112
(10 nmol, Figure 5B) each prevented the effect of icilin
(10 nmol, Figure 4A). Similarly, the analgesia produced
by intrathecal (2)-menthol (200 nmol, Figure 4B) was
reversed by intrathecal LY 341495 and UBP 1112. The
mean percentage reversal of sensitization over 20–30
min postinjection was 86.1% 6 8.1% for PWL and
80.6%6 4.2% for PWT with (2)-menthol alone, 22.0%6
6.9% for PWL and 7.1% 6 7.1% for PWT with menthol
and LY 341495, and 9.2% 6 6.9% for PWL and 0.0% 6
0.0% for PWT with (2)-menthol and UBP 1112 (n = 6).
Neither LY 341495 nor UBP 1112 had any effects alone
(data not shown), suggesting that Group II/III mGluRs
show little tonic activation after CCI, but are specifically
utilized downstream of icilin. In contrast, intrathecal co-
administration of them-opioid receptor antagonist nalox-
one (25 nmol) with icilin had no effect (Figure 5C), indicat-
ing that icilin analgesia is opioid independent. To avoid
any possibility of nonspecific drug interactions, we also
administered icilin (200 mM) topically, but the mGluR
antagonists intrathecally. Figure 5D shows that the icilin
reversal of thermal and mechanical sensitization in this
case was again prevented by LY 341495 or UBP 1112.
The analgesic effect of skin cooling to 16C (Figure 1E)
was also prevented by intrathecally applied LY 341495
(5 nmol) or UBP 1112 (10 nmol). The mean percentage
reversal of ipsilateral CCI-induced reductions in PWT
caused by cooling was 0.0% 6 0.0% in the presence of
either drug (n = 5).
To confirm the analgesic effect of icilin at the level of
single spinal cord neurons, we made in vivo extracellular
recordings of large lamina I and III/IV neurons (which in-
tegrate nociceptive and nonnociceptive inputs). Topical
administration of icilin (200 mM) to the peripheral recep-
tive field area ipsilateral to CCI caused inhibition of the el-
evated neuronal responses to motorized rotating brush(Figure 5E). In the eight neurons out of 12 that were af-
fected by icilin (two in lamina I and six in laminae III/IV)
brush-induced responses were reduced to 37.4% 6
5.5%, p < 0.001). Vehicle had no effect. Contralateral
neurons were unaffected (111.9% 6 8.9% of control;
n = 6). As an example of one of the Group II/III mGluR an-
tagonists investigated on reflexes, UBP 1112 was iono-
phoresed in the vicinity of recorded dorsal-horn neurons
at currents of 20–60 nA. UBP 1112 reversed the effect of
icilin; the brush-induced firing rate reverted to 80.2% 6
9.3% of control values (Figure 5E), but UBP 1112 had
no effect alone, and nor did saline current controls.
Because some Group II/III mGluRs may be postsyn-
aptic, we asked whether icilin could reverse the addi-
tional sensitization of behavioral-reflex responsiveness
caused by intrathecally applied NMDA in CCI animals.
Icilin (10 nmol) clearly attenuated the additional ipsilat-
eral sensitization induced by 3.75 nmol of NMDA plus
0.75 nmol of its coagonist site activator, ACPC, injected
intrathecally. Ipsilateral PWL values in thermal tests
were 10.1 6 0.6 s at baseline and decreased to 7.9 6
0.3 s (15–30 min after injection of NMDA/ACPC), but
increased to 14.9 6 0.6 s in the additional presence of
icilin. Contralateral values were unaltered by icilin or
NMDA/ACPC. Ipsilateral PWT values in mechanical tests
were 1504.2 6 105.3 mN/mm2 at baseline, 891.6 6 27.3
mN/mm2 after injection of NMDA/ACPC, and 3482.7 6
174.3 mN/mm2 with coinjection of icilin (mean 6 SEM,
n = 6). Contralateral values again were unaltered. A com-
ponent of the central events elicited by icilin may there-
fore be postsynaptic, although it is important to note
that functional NMDA receptors may also be present
on afferent terminals [52].
Discussion
Little is known of the mechanism underlying cooling-
induced analgesia, but a number of cool-sensitive ion
channels, including TRPM8, have recently been identi-
fied in somatosensory afferents [13]. We now show
that TRPM8 activation reverses nerve-injury-induced
hypersensitivity. TRPM8 can be activated by menthol
[15, 16], which is analgesic in hot-plate and acetic-acid
writhing tests [11], although menthol can produce pain
at very high doses [53, 54]. Here, either topical or intra-
thecal application of (2)-menthol produced behavioral
analgesia in the CCI model of neuropathic pain, most
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1600Figure 5. Icilin-Induced Analgesia after CCI Is Prevented by Group II and III mGluR Antagonists
(A–D) Paw withdrawal latency (PWL, s) to noxious heat and paw withdrawal threshold (PWT, mN/mm2) to mechanical stimuli ipsilateral (B) or
contralateral (-) to CCI. Data represent mean 6 SEM, with an n of six animals in each case. Rats were intrathecally injected (at arrow). Icilin
(10 nmol) was coadministered with (A) the Group II mGluR antagonist LY 341495 (5 nmol), (B) the Group III mGluR antagonist UBP 1112 (10
nmol), or (C) the opioid receptor antagonist, naloxone (25 nmol).
(A and B) When either LY 341495 or UBP 1112 was coadministered with icilin, it abolished the analgesic effect of icilin as indicated by the
persistence of sensitized (*, p < 0.05) PWT/PWL responses ipsilateral to nerve injury.
(C) Naloxone coadministration with icilin did not prevent the icilin-induced analgesia seen in PWT and PWL responses ipsilateral to nerve injury
(y, p < 0.05). * indicates significant ipsilateral-contralateral differences, and y indicates significant ipsilateral analgesic effect of drug (p < 0.05).
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with another TRPM8 activator, icilin [15]. As with men-
thol, very high doses of icilin were found to cause a gen-
eralized increase in sensitization, affecting CCI animals
bilaterally and naive animals in a similar fashion (Table
1). Importantly, analgesic effects of icilin were seen at
200-fold-lower concentrations than those causing non-
specific sensory changes. Specific involvement of
TRPM8 in the reversal of neuropathic sensitization was
confirmed by the abrogation of icilin analgesia after in-
trathecal infusion of a TRPM8 antisense oligonucleotide
to knock down TRPM8 expression. Furthermore, the an-
algesic profile was mimicked by cutaneous cooling to
20C–16C, a range activating the TRPM8 channel [14].
Icilin and menthol were applied cutaneously in solution
at 30C, so any possible drug effects on skin tempera-
ture were avoided. TRPM8 antisense had no effect alone
on CCI-induced sensitized responses to noxious heat,
mechanical stimuli, or intense cold (Figure 3), similar to
observations made in an alternative neuropathic pain
model [27]. A role for the TRPA1 channel in analgesia
seems unlikely because selective TRPA1 activators, cin-
namaldehyde, allicin, and diallyl disulphide, caused
contrasting sensitization/hyperalgesia not only after
CCI, but also in naive animals. The analgesic effects of
icilin were only seen in the sensitized pain state, but
were not restricted to nerve injury, because sensitization
due to peripheral inflammation, afferent demyelination,
and TRPA1 activation was also reduced. The significant
behavioral and electrophysiological effects of topically
applied icilin demonstrate that icilin can cross the skin
sufficiently to excite peripheral afferents, and point to
the likely clinical utility of this or related drugs.
The precise identity of the TRPM8-containing cool-re-
sponsive afferents is not clear. Subpopulations of Ad fi-
bers and C fibers are responsive to different ranges of
cool temperatures:w15C–30C and <15C [55, 38]. In-
nocuous cooling (15C–30C) activates a subpopulation
of Ad fibers and C fibers in primates, but almost solely
unmyelinated fibers in rodents [55]. In contrast, intense
noxious cold is signaled by unmyelinated polymodal no-
ciceptors, which also respond to heat and mechanical
stimuli [38]. The TRPM8 activator menthol activates
cool-sensitive fibers and sensitizes stimulus-induced
responses in the range 20C–30C [56, 57]. Studies of
TRPM8 in vitro identify this channel as a likely trans-
ducer of moderate cool temperatures [20]. In DRG and
trigeminal cultures, responses to menthol, cooling
(15C–30C), and TRPM8 mRNA expression all correlate
closely [18–20]. TRPM8 is expressed in 5%–20% of DRG
cell bodies that are small and presumed Ad fibers or C
fibers [15, 16], but not in large myelinated fibers. We
observed that TRPM8 immunoreactivity is normallyassociated with a subpopulation of peripherin-positive
C fibers, but only minimally with NF-200-positive affer-
ents, whereas high-sensitivity cRNA hybridization sug-
gests the presence of some TRPM8 mRNA in up to
19% of NF-200-positive afferents [58]. The capsaicin-
and heat-sensitive TRPV1 channel, which contributes
to thermal nociception and inflammatory sensitization
[12], is found both in peptidergic afferents (w85%) and
in nonpeptidergic (isolectin-B4, IB4-positive) cells in
the rat [59]. TRPM8 is not categorically associated with
either peptidergic or IB4-positive afferents [15] but is of-
ten present in those containing the NGF receptor, Trk A
[58]. Different groups have reported coexpression of
mRNAs for TRPM8 and TRPV1 or menthol/capsaicin re-
sponsiveness of DRG at 29%–50% [15, 20, 60] or close
to zero [14, 16, 58]. Overall, it seems likely that TRPM8
is normally expressed in a distinct population of cool-re-
sponsive afferents and possibly also to an extent in some
nociceptors. Our findings further identified increased ex-
pression in peripherin-positive C fibers, but induction in
small NF-200-positive presumed Ad fibers [35], suggest-
ing that plasticity in TRPM8 expression may participate
in icilin analgesia in neuropathic pain. No changes in
DRG expression of TRPM8 were reported in an alterna-
tive neuropathic pain model (ligation of L5 spinal nerve
or indeed after CFA) [26, 27], suggesting that specific
aspects of the particular model, such as the coexistence
of injured and uninjured afferents in DRG after CCI, may
be important in TRPM8 upregulation.
TRPA1, which has also been proposed as a cool re-
ceptor [14], appears to play an entirely different role, elic-
iting reflex pain behaviors in naive animals, as well as in-
creasing thermal and mechanical responsiveness in the
neuropathic state. This may correspond to clinical ob-
servations after nerve injury in which moderately cool
stimuli are perceived as painful [1]. TRPA1 is present
mainly in small cells in sensory ganglia [14, 21] and
may increase ipsilateral to nerve injury and inflammation
[26, 27]. Nerve-injury- and inflammation-induced hyper-
algesia to noxious cold (5C) is reported to be decreased
by antisense knockdown of TRPA1 [26, 27]. Correspond-
ingly, mutant mice homozygous for targeted disruption
of the TRPA1 gene show reduced reflex withdrawal re-
sponses to selective TRPA1 activators and reduced sen-
sitization of noxious heat and innocuous mechanical re-
sponses caused by these agents [24]. However, the role
of TRPA1 in noxious cold responses is disputed, with re-
sults from different lines of TRPA12/2 animals showing
either attenuated or unaltered coldplate withdrawal re-
sponses [24, 25]. Thus the precise role of TRPA1 in
cold sensation remains unclear, but here as in other
studies TRPA1 clearly acts in a pronociceptive manner
[21, 22, 46, 47]. Although icilin may interact with low(D) The analgesic effects of topically applied icilin (200 mM at 30C) were also reversed by intrathecal injection of Group II/III mGluR antagonists.
The figure shows mean % reversal of the ipsilateral/contralateral difference in either PWL or PWT measured over 15–30 min after 5 min topical
application of icilin, with or without concurrent intrathecal injection of LY 341495 (5 nmol) or UBP 1112 (10 nmol), or after mGluR antagonists
alone.
(E) Typical extracellular recording of a single dorsal-horn neuron ipsilateral to CCI, responding to continuous motorized brushing of the cutane-
ous receptive field on the hind paw and the effects of icilin (200 mM at 30C) topically applied to an adjacent area of the receptive field. Similar
results were observed in 8 out of 12 neurons with examples in both laminae III/IV and lamina I. Neuronal firing is displayed as action potentials per
second (Hz) plotted against time. (Ei) Brush-evoked firing in neurons ipsilateral to nerve injury was consistently inhibited by topically applied ici-
lin; (Eii) this effect was reversed by ionophoresis of UBP 1112 at 20–60 nA; (Eiii) recovery was observed after removal of the UBP 1112 ejection
current. Neurons contralateral to nerve injury were unaffected by icilin, and topical vehicle had no effect. In addition, ionophoresis of UBP 1112
alone or saline current controls showed no discernable effect.
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sible Mechanistic Basis for TRPM8-Mediated
Analgesia after CCI
In this simplified hypothetical model, activa-
tion of TRPM8 in a subpopulation of affer-
ents by icilin, menthol, or moderate cooling
leads to central synaptic release of glutamate
(Glu), which then acts through inhibitory
Group II/III mGluR receptors located either
presynaptically on injury-activated nocicep-
tive afferents or perhaps also postsynapti-
cally on dorsal-horn neurons, thereby attenu-
ating neuropathic sensitization.potency at the TRPA1 channel [14], the analgesic profile
of TRPM8 activators here is entirely different from the
pronociceptive profile of TRPA1 activators. The extent
of TRPM8/TRPA1 coexpression in afferents is reported
to be minimal [14, 58].
The analgesia induced by icilin and menthol and by
skin cooling to 16C was shown to be centrally mediated
and dependent on Group II/III mGluRs. The lack of effect
of naloxone suggests independence from classical opi-
oid analgesia. Furthermore, at the doses used, mGluR
Group II/III antagonists selectively reversed icilin and
menthol analgesia in sensitized responses, without any
effects alone. Group II/III mGluRs are known to inhibit
nociceptive responses [30–32, 48, 49], and we showed
that Group II/III mGluR agonists selectively inhibit sensi-
tized responses in neuropathic pain. Both Group II and III
mGluR subtypes are expressed in primary afferents,
especially IB4-positive cells [28, 50, 51]. Activation of
Group II/III mGluRs can inhibit afferent-evoked poten-
tials in the dorsal horn [48], because Group II mGluRs
are both pre- and postsynaptic at primary afferent
synapses [29], whereas Group III mGluRs are largely pre-
synaptic [51]. Menthol is reported to increase mEPSC
frequency at some synapses between DRG and dorsal-
horn neurons in culture and in slices [44, 45], presumably
corresponding to the activation of TRPM8-containing
afferents (Figure 1D) and increased release of glutamate.
Figure 6 shows a schematic outline of a model in which
glutamate released from TRPM8-expressing afferents
could mediate icilin-induced analgesia by acting on
Group II/III mGluRs (located presynaptically on nocicep-
tive afferents and possibly also postsynaptically) to
result in attenuation of pain-related sensitization
(Figure 5E) and behavioral analgesia (Figure 5D).
Conclusions
In summary, these novel findings show that both periph-
eral and central activation of TRPM8 can produce an an-
algesic effect that specifically reverses the sensitization
of behavioral reflexes elicited by peripheral nerve injury.
This effect is produced by very low concentrations of
topically applied TRPM8 activators, pointing to the likeli-
hood of its ready utility in a clinical context. Other sensi-
tized pain states, in addition to that induced by nerve
injury, are similarly sensitive to reversal by TRPM8 acti-
vation, emphasizing the likely value of TRPM8 activators
and downstream central mediators of TRPM8 action,such as Group II/III mGluRs, as targets for the develop-
ment of novel analgesics.
Experimental Procedures
Animals
All experiments were conducted in accordance with the UK Animals
(Scientific Procedures) Act, 1986, and guidelines of the University of
Edinburgh. Adult male Wistar rats (Harlan, United Kingdom) weigh-
ing 120–250 g were used for all experiments.
Neuropathic and Inflammatory Pain Models
Pain models were generated under halothane anesthesia (Zeneca,
Cheshire, United Kingdom). For the chronic constriction injury
(CCI) model of neuropathic pain, four ligatures were tied loosely to
constrict the sciatic nerve at midthigh level (as described previously
[61]). An inflammatory pain model was generated by injecting 100 ml
of Complete Freund’s Adjuvant (CFA, Sigma-Aldrich) into the ventral
surface of the right hind paw [61]. A model of peripheral demyelin-
ation-induced pain was produced by focal application of lysolecithin
to the sciatic nerve [43]. Peak behavioral sensitization was observed
postsurgically between days 10 and 16 for CCI, 1 and 3 for CFA, and
7 and 14 for lysolecithin, when pharmacological and electrophysio-
logical experiments and tissue removal were conducted.
Behavioral Testing
Thermal sensitivity was assessed by measuring paw withdrawal la-
tency (PWL, s) in response to a noxious thermal stimulus (Har-
greaves’ thermal stimulator, Linton Instrumentation, Diss, United
Kingdom) directed to the hind paw midplantar glabrous surface. Me-
chanical sensitivity was recorded as the paw withdrawal threshold
(PWT, mN/mm2) to calibrated von Frey filaments (Stoelting, Illinois),
as previously described [61]. Sensitivity to noxious cold was as-
sessed by placing animals in a water bath with an aluminium floor
containing 1-cm-deep 4C water and counting the time the paw
was held suspended over a 20 s period.
Intrathecal Application of Drugs
The following drugs were applied intrathecally in a 50 ml volume of
saline-based vehicle at 37C: icilin (2.5–200 mM in saline with 0.2%
dimethylformamide, DMF); LY 341495 (100 mM in saline); UBP 1112
(200 mM in saline); 2R, 4R-APDC [(2R, 4R)-4-aminopyrrolidine-2,4-di-
carboxylate, 300 mM in saline]; ACPT-III [(1R,3R,4S)-1-aminocyclo-
pentane-1,3,4-tricarboxylic acid, 3 mM in saline]; AP-4 [(L-(1)-2-
amino-4-phophonobutyric acid, 3 mM in saline); naloxone (0.5 mM
in saline); NMDA (75 mM in saline) and ACPC (1-aminocyclopropane-
carboxylic acid, 15 mM in saline) (Tocris Cookson, Bristol, United
Kingdom); (2)-menthol [1R, 2S, 5R-(2)-menthol, 4 mM in saline]; cin-
namaldehyde (1.5 mM in saline); Ruthenium Red (5 mM in saline)
(Sigma-Aldrich, United Kingdom); allicin (0.5 mM in saline with
0.5% DMF); and diallyl disulphide (DADS, 1 mM in saline with
0.5% DMF) (LKT Laboratories, St. Paul, Minnesota). Drugs were in-
jected into the L5–6 intrathecal space under brief halothane anesthe-
sia, with a 25-gauge needle microsyringe (BD Biosciences, Oxford),
as described previously [61] in animals that were at peak levels of
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min after injection to allow recovery from anesthesia [43, 62, 63]
and continued every 5 min thereafter until readings returned to base-
line levels (n = 6 in each case). We, and others [43, 62, 63], find com-
plete recovery from anesthetic by 15 min. All appropriate controls
were carried out to eliminate the possibility of effects due to vehicle
or to injection procedure.
The TRPM8 channel activators icilin and (2)-menthol were tested
in CCI and naive animals. The effects of icilin were additionally as-
sessed in animals with CFA-induced inflammation or with lysoleci-
thin-induced demyelination. Icilin was also coadministered with
the m-opioid receptor antagonist naloxone, the Group II metabo-
tropic glutamate receptor (mGluR) antagonist LY 341495, or the
Group III mGluR antagonist UBP 1112. The effects of these antago-
nists alone, as well as effects of the Group II mGluR agonist 2R, 4R-
APDC and the Group III mGluR agonists ACPT-III and AP-4, were
assessed in CCI animals. The TRPA1 channel activator cinnamalde-
hyde, alone and with icilin, was tested in CCI animals and in naive
animals. Further TRPA1 channel activators, allicin and diallyl disul-
phide, were assessed in naive animals. Both icilin and cinnamalde-
hyde effects in CCI animals were also investigated in the additional
presence of Ruthenium Red.
Topical Application of Drugs
Icilin was applied at concentrations of 2.5–500 mM (in water with
0.2% DMF), by placing CCI or naive rats unrestrained for 5 min in a
1-cm-deep water bath (sufficient to cover paws), which was thermo-
statically controlled to a temperature of 30C, or by very lightly anes-
thetizing rats and immersing hind paws in small tubes containing 5
ml icilin (500 mM–5 mM, with a vehicle of 45% dimethylformamide
in 0.2% aqueous Tween 80) for 5 min, followed by sensory testing
for 60–80 min. The effects of (2)-menthol and its stereoisomers iso-
menthol (1S, 2R, 5R-menthol,) and (+)-menthol [1S, 2R, 5S (+)-men-
thol] (4–16 mM in 80% ethanol) were also assessed. Relevant vehi-
cles were always assessed in similar experiments. As a contrast,
the effect of cinnamaldehyde (1.5 mM in water) and the effect of cin-
namaldehyde with additional icilin (80 mM in water with 0.2% DMF)
were assessed in naive animals. The effects of icilin (80 mM) were fur-
ther assessed in CCI animals that had undergone antisense and mis-
sense treatment for knockdown of TRPM8 or immediately after
intrathecal injection of either LY 341495 or UBP 1112. Actual skin
temperatures were measured by a subcutaneous thermistor probe
and were found to equilibrate to around 0.5C above bath tempera-
ture. The effects of brief paw immersion at different temperatures
(10C–22C for 5 min) on CCI rats were assessed by mechanical test-
ing. The effects of intrathecal LY 341495 or UBP 1112 on the reversal
of ipsilateral sensitization in CCI after a 16C cool challenge for 5 min
were measured. Reflex testing commenced 5 min after challenge,
unless animals had been anesthetized, in which case 15 min was al-
lowed for recovery. Six replicate animals were tested in all pharma-
cological experiments.
Dorsal Rhizotomy
To establish whether TRPM8 expression in the spinal cord was pre-
dominantly pre- or postsynaptic, we performed a unilateral L2–6
dorsal rhizotomy under anesthesia, following laminectomy to ex-
pose the dorsal roots. Eight days later, tissue was removed and pro-
cessed for immunohistochemistry.
Western Blots
Experiments were performed by standard procedures as previously
described [61]; for more details see the Supplemental Data available
online.
Immunohistochemistry
Experiments were performed as previously described [43]; for more
details, see Supplemental Data.
Antisense Knockdown of TRPM8
Antisense and missense oligonucleotides were 22 mers with phos-
phorothioate bonds at the last two positions at the 50 and 30 ends
(MWG Biotech, Ebersberg, Germany). Antisense extended from
base 210 to base +12 relative to the start of the open reading frame
for the rat TRPM8 gene: 50 C*T*CGAAGGACATCTTGCCGT*G*G 30,where * represents phosphorothioate linkages. Missense was de-
signed with four inversions of C/G or A/T as appropriate at residues
3, 11, 14, and 22, preserving overall G/C content. BLAST searches of
both oligonucleotides indicated no significant complementarity to
any known gene sequence. Fourteen day or seven day osmotic min-
ipumps (for CCI experiments or naive electrophysiology experi-
ments, respectively—Alzet Minipump, models 2002, 2001; Charles
River, United Kingdom) containing oligonucleotides (1 mg/ml in sterile
saline) were connected to canulae inserted under the dura of the spi-
nal cord to level L5–6 and produced a predicted infusion rate of 0.5
ml/hr. CCI surgery was performed at the same time as minipump im-
plantation. Sensory tests were carried out to assess the time course
of behavioral sensitization in animals that had also undergone a CCI
injury. Icilin was applied topically rather than intrathecally so as to
prevent any interference with the infusion canula. Peripheral nerve
recordings and tissue harvesting were carried out after an interval
of 4–5 days to allow time for protein knockdown.
Electrophysiology
Peripheral
Recordings of saphenous (sensory) nerve were made in naive ani-
mals (n = 7) to assess the effects of topical icilin on primary afferents.
In addition, recordings were carried out on animals that had under-
gone TRPM8 antisense or missense treatment beginning 4–5 days
previously. Rats were anesthetized (with 0.6 ml 25% urethane/100
g, intraperitoneal), and the saphenous nerve was exposed and dis-
sected from its associated vein and artery. Further dissection under
liquid paraffin enabled identification of afferent preparations com-
prising a small number of fibers. The conduction velocity of single
identified afferent fibers was determined by using bipolar electrodes
and the peripheral stimulus technique [64]. After isolation of prepa-
rations, icilin (200 mM in water with 0.2% DMF), (2)-menthol (4 mM in
25% ethanol), resiniferatoxin (1 mM in ethanol), or vehicle alone was
applied to the hind limb receptive fields, and neuronal responses
were recorded with the Chart program (version 3.6).
Central
Recordings of spinal dorsal-horn neurons were made in CCI ani-
mals, as described previously [61]. After halothane induction, the
jugular vein and trachea were canulated and intravenous anesthetic
was delivered: a-chloralose (0.6 mg/kg, Fisher) and urethane (1.2
mg/kg, Sigma), with small supplementary doses of a-chloralose as
required throughout the experiment. Core body temperature was
maintained at 37C–38C by means of a thermostatically controlled
heated blanket. The animal was placed in a stereotaxic frame, and
the thoracolumbar spinal column was supported by three pairs of
swan-necked clamps. A laminectomy was performed at L2–L5,
and agar (2% in saline at 37C) was delivered over exposed cord
to increase mechanical stability. Above the recording region, the
agar and spinal cord dura were removed, and liquid paraffin was
poured into the pool. Extracellular recordings were made from single
multireceptive neurons in laminae I–IV through the center barrel of
a seven-barrelled glass microelectrode filled with 4 M NaCl (tip-
diameter 4–5 mm, DC resistance 5–8 MU). The receptive fields of
hair-follicle innervated neurons on the distal hind limb were identi-
fied by an innocuous brush stimulus [61]. Icilin (200 mM in water
with 0.2% DMF) was applied peripherally to the receptive field of in-
dividual recorded neurons, and the effect on neuronal response to
a rotating brush was recorded and analyzed with Spike2 program
(Version 3.2, CED). The Group III mGluR antagonist UBP 1112 (20
mM in water), pH 8.5, and control 1 M NaCl, pH 8.5, were ionophor-
esed from the side barrels of the electrode by using currents of
between 20 nA and 80 nA (Neurophore BH2 ionophoresis system,
Medical Systems, Great Neck, New York) to measure effects on neu-
ronal response to icilin.
Statistics
All data were analyzed for statistical significance by using Sigmastat
software (version 2.03) with p values < 0.05 being considered signif-
icant. Differences in thermal sensitivity between the paw ipsilateral
to nerve injury and the contralateral paw were assessed with Stu-
dent’s t test. Any effect of drug treatment was analyzed by one-
way repeated-measures ANOVA followed by Dunnett’s post-hoc
multiple-comparisons test. The equivalent nonparametric tests
for mechanical sensitivity were Wilcoxon rank test for
Current Biology
1604ipsilateral:contralateral differences and Friedman repeated-mea-
sures ANOVA followed by Dunn’s test for changes from predrug
control values. Western blot-densitometric values were compared
by using the Wilcoxon test, immunohistochemistry cell counts
were analyzed by one-way ANOVA, and electrophysiological spike
frequencies were analyzed by one-way ANOVA on ranks.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures
and are available with this article online at: http://www.current-
biology.com/cgi/content/full/16/16/1591/DC1/.
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